.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

UBS
McKinsey
Boehringer Ingelheim
Covington
Novartis
Express Scripts
Dow
QuintilesIMS
Harvard Business School
Deloitte

Generated: September 21, 2017

DrugPatentWatch Database Preview

LOESTRIN 24 FE Drug Profile

« Back to Dashboard

Which patents cover Loestrin 24 Fe, and when can generic versions of Loestrin 24 Fe launch?

Loestrin 24 Fe is a drug marketed by Apil and is included in one NDA.

The generic ingredient in LOESTRIN 24 FE is ethinyl estradiol; norethindrone acetate. There are twenty-six drug master file entries for this compound. Twenty-three suppliers are listed for this compound. Additional details are available on the ethinyl estradiol; norethindrone acetate profile page.

Summary for Tradename: LOESTRIN 24 FE

Patents:0
Applicants:1
NDAs:1
Suppliers / Packagers: see list3
Clinical Trials: see list1
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:LOESTRIN 24 FE at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Apil
LOESTRIN 24 FE
ethinyl estradiol; norethindrone acetate
TABLET;ORAL021871-001Feb 17, 2006ABRXYesNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: LOESTRIN 24 FE

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Apil
LOESTRIN 24 FE
ethinyl estradiol; norethindrone acetate
TABLET;ORAL021871-001Feb 17, 2006► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: LOESTRIN 24 FE

Drugname Dosage Strength RLD Submissiondate
norethindrone acetate/ ethinyl estradiol and ferrous fumarateTablets1 mg/0.02 mg and 75 mgLoestrin 24 Fe4/17/2006
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Express Scripts
McKesson
Covington
UBS
Daiichi Sankyo
Citi
Farmers Insurance
Chinese Patent Office
Moodys
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot